Physician profile
Lawrence E Gering
NPI 1710986443
$5,171.18
in general payments reported to CMS, 2019-2025
17 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $487 · 2021: $649 · 2022: $279 · 2023: $484 · 2024: $478 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568 · Travel and Lodging: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.66 |
| Travel and Lodging | $900.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,423.78 | 2019-2025 | Watchman Access System, Watchman Flx |
| Janssen Pharmaceuticals, INC | $828.25 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $598.22 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $436.29 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $336.86 | 2019-2025 | |
| Abbott Laboratories | $335.30 | 2019 | |
| Pfizer INC. | $287.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.61 | 2020-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.04 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Heartflow, INC. | $86.23 | 2022 | |
| Sanofi-Aventis U.S. LLC | $77.41 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $71.73 | 2022 | |
| Merck Sharp & Dohme LLC | $55.27 | 2022-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $50.13 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $28.01 | 2019-2024 | Brilinta |
| Kiniksa Pharmaceuticals International, Plc | $23.63 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Gering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.